Denali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target

In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics, with a price target of $38.00.

Thomas Shrader has given his Buy rating due to a combination of factors, starting with the clear superiority of AVLAYAH over current standard therapy, as shown by dramatic improvements in key biomarkers that are tightly linked to disease progression and survival. He expects that most newly diagnosed patients will start on AVLAYAH, and over time a growing adult patient pool paying high annual treatment costs should meaningfully expand long‑term revenue potential.

In addition, Shrader points to Denali’s blood–brain barrier shuttle platform as a core strategic asset that can be leveraged across multiple enzyme replacement and CNS indications, including promising candidates like DNL593 for FTD and DNL952 for Pompe, which have already shown enhanced tissue uptake and substrate clearance. Combined with a constructive FDA relationship, a clear regulatory path for complex biologics, and valuation support from his DCF framework, these factors underpin his conviction that DNLI shares warrant a Buy rating and an increased price target.

In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $42.00 price target.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DNLI in relation to earlier this year.